Candel Therapeutics, Inc. (CADL)

Market Cap	352.32M +2.5%
Revenue (ttm)	n/a
Net Income	-38.18M
EPS	-0.72
Shares Out	73.25M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,315,765
Open	4.890
Previous Close	4.880
Day's Range	4.760 - 4.961
52-Week Range	4.250 - 7.700
Beta	-0.90
Analysts	Strong Buy
Price Target	19.71 (+309.77%)
Earnings Date	Mar 12, 2026

About CADL

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery pl...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 27, 2021
• Employees: 55
• Stock Exchange: NASDAQ
• Ticker Symbol: CADL
• Website: https://www.candeltx.com

Analyst Summary

According to 7 analysts, the average rating for CADL stock is "Strong Buy." The 12-month stock price target is $19.71, which is an increase of 309.77% from the latest price.

Price Target

$19.71

(309.77% upside)

Analyst Consensus: Strong Buy